Abstract
Prostate cancer is currently the most prevalent cancer among men in the United States and ranks second to lung cancer in terms of annual mortality. The androgen receptor (AR) is central to the initiation and growth of prostate cancer and to the therapeutic response to hormones. Although it has been known for many years that the expression and activity of AR is controlled by AR coregulators, the manipulation of endogenous AR coregulators to affect AR levels or function has not been widely exploited clinically. Coregulators are proteins that interact with AR to either enhance (coactivators) or reduce (corepressors) transcriptional activity. They act via a variety of mechanisms that provide potential therapeutic targets. The purpose of this article is to review the evidence for the deregulated expression and activity of AR associated coregulators in the progression of prostate cancer. The therapeutic use of these coregulators in both clinical and preclinical models is discussed with the aim of suggesting new modalities for prostate cancer treatment.
Keywords: Prostate cancer, androgen receptor, AR coactivators, AR corepressors
Current Cancer Therapy Reviews
Title: New Therapies for Prostate Cancer Based on the Biology of Androgen Receptor Coregulators
Volume: 6 Issue: 3
Author(s): Yuexing Zhang and Anne W. Hamburger
Affiliation:
Keywords: Prostate cancer, androgen receptor, AR coactivators, AR corepressors
Abstract: Prostate cancer is currently the most prevalent cancer among men in the United States and ranks second to lung cancer in terms of annual mortality. The androgen receptor (AR) is central to the initiation and growth of prostate cancer and to the therapeutic response to hormones. Although it has been known for many years that the expression and activity of AR is controlled by AR coregulators, the manipulation of endogenous AR coregulators to affect AR levels or function has not been widely exploited clinically. Coregulators are proteins that interact with AR to either enhance (coactivators) or reduce (corepressors) transcriptional activity. They act via a variety of mechanisms that provide potential therapeutic targets. The purpose of this article is to review the evidence for the deregulated expression and activity of AR associated coregulators in the progression of prostate cancer. The therapeutic use of these coregulators in both clinical and preclinical models is discussed with the aim of suggesting new modalities for prostate cancer treatment.
Export Options
About this article
Cite this article as:
Zhang Yuexing and W. Hamburger Anne, New Therapies for Prostate Cancer Based on the Biology of Androgen Receptor Coregulators, Current Cancer Therapy Reviews 2010; 6 (3) . https://dx.doi.org/10.2174/157339410791698205
DOI https://dx.doi.org/10.2174/157339410791698205 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regulatory Overview of Biosimilars: Current Scenario and Future Opportunities
Applied Clinical Research, Clinical Trials and Regulatory Affairs Bergamot Juice Extract Inhibits Proliferation by Inducing Apoptosis in Human Colon Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Metabolic Profiling and Imaging of Prostate Cancer
Current Metabolomics High-Risk HPV/ErbB-2 Interaction on E-Cadherin/Catenin Regulation in Human Carcinogenesis
Current Pharmaceutical Design A Medicinal Mushroom: Phellinus Linteus
Current Medicinal Chemistry Fluorinated Natural Products with Clinical Significance
Current Topics in Medicinal Chemistry Editorial [Hot topic: Apoptosis in Carcinogenesis and Cancer Therapy (Guest Editors: George G. Chen and Paul B.S. Lai)]
Current Cancer Drug Targets Targeting the Hippo Pathway for Anti-cancer Therapies
Current Medicinal Chemistry Prevention and Treatment of Regimen-Related Mucosal Toxicity
Recent Patents on Anti-Cancer Drug Discovery G4 Aptamers: Trends in Structural Design
Mini-Reviews in Medicinal Chemistry Stimulation of Peroxisome Proliferator-Activated Receptor-Gamma (PPARγ) using Pioglitazone Decreases the Survival of Acute Promyelocytic Leukemia Cells through Up-Regulation of PTEN Expression
Anti-Cancer Agents in Medicinal Chemistry A New Era of Immunotherapy in Prostate Cancer
Current Molecular Pharmacology The Benefits and Side Effects of Bevacizumab for the Treatment of Recurrent Ovarian Cancer
Current Drug Targets Tumor Immune Escape Mechanisms that Operate During Metastasis
Current Pharmaceutical Biotechnology Perspective of MiRNAs in Clinical Glioblastoma Research
Current Signal Transduction Therapy Current HPLC Methods for Assay of Nano Drug Delivery Systems
Current Topics in Medicinal Chemistry Multidisciplinary Cancer Therapy with Telomerase-Specific Oncolytic Adenovirus
Current Cancer Therapy Reviews Novel N-mustard-benzimidazoles/benzothiazoles Hybrids, Synthesis and Anticancer Evaluation
Anti-Cancer Agents in Medicinal Chemistry Biological Relevance of DNA Polymerase Beta and Translesion Synthesis Polymerases to Cancer and its Treatment
Current Molecular Pharmacology Cholangiocarcinoma Therapeutics: An Update
Current Cancer Drug Targets